Profile data is unavailable for this security.
About the company
POINT Biopharma Global Inc. is a radiopharmaceutical company. The Company, through its subsidiaries is focused on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The Company's clinical-stage product candidates include PNT2003 and PNT2002 for the treatment of prostate cancer and neuroendocrine tumors. Its preclinical stage product candidates include Lu-PNT2004 and Lu-PNT2001. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2004 is a family of fibroblast activation protein-alpha (FAP-alpha), which targeted radioligands. PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-79.17m
- Incorporated2020
- Employees72.00
- LocationPOINT Biopharma Global Inc4850 West 78Th Street, 18Th FloorINDIANAPOLIS 46268United StatesUSA
- Phone+1 (317) 543-9957
- Fax+1 (302) 655-5049
- Websitehttps://www.pointbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals Inc | 316.39m | -49.52m | 697.54m | 600.00 | -- | 2.22 | 68.85 | 2.20 | -3.05 | -3.05 | 19.46 | 19.34 | 0.4131 | 1.48 | 2.15 | 527,308.30 | -6.25 | -3.38 | -7.12 | -4.08 | 56.13 | 59.73 | -15.14 | -7.96 | 2.40 | -1.05 | 0.4584 | -- | 46.38 | 12.34 | -15.72 | -- | -3.06 | -- |
| Arcutis Biotherapeutics Inc | 3.69m | -311.46m | 706.12m | 268.00 | -- | 3.37 | -- | 191.57 | -5.65 | -5.65 | 0.067 | 3.43 | 0.0086 | -- | 0.8358 | 13,753.73 | -72.65 | -65.51 | -79.22 | -70.91 | 79.54 | -- | -8,449.76 | -19,390.75 | 11.37 | -19.27 | 0.4855 | -- | -- | -- | -50.93 | -- | -- | -- |
| Ideaya Biosciences Inc | 50.93m | -58.66m | 707.91m | 103.00 | -- | 2.02 | -- | 13.90 | -1.40 | -1.40 | 1.22 | 7.25 | 0.1324 | -- | 77.52 | 494,475.70 | -15.25 | -20.08 | -16.94 | -22.40 | -- | -- | -115.17 | -222.78 | -- | -- | 0.00 | -- | 82.28 | -- | -17.87 | -- | 14.40 | -- |
| Anavex Life Sciences Corp | 0.00 | -50.07m | 710.09m | 38.00 | -- | 5.26 | -- | -- | -0.6463 | -0.6463 | 0.00 | 1.73 | 0.00 | -- | -- | 0.00 | -32.80 | -46.07 | -35.57 | -51.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.56 | -- | -- | -- |
| IGM Biosciences Inc | 697.00k | -219.17m | 731.05m | 242.00 | -- | 2.23 | -- | 1,048.85 | -5.68 | -5.68 | 0.0179 | 7.67 | 0.0016 | -- | -- | 3,630.21 | -50.20 | -- | -54.23 | -- | -- | -- | -31,444.48 | -- | -- | -- | 0.00 | -- | -- | -- | -103.02 | -- | -- | -- |
| Viking Therapeutics Inc | 0.00 | -68.87m | 735.57m | 21.00 | -- | 5.05 | -- | -- | -0.8964 | -0.8964 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -36.32 | -18.38 | -39.53 | -19.17 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.24 | -- | -- | -- |
| Cogent Biosciences Inc | 0.00 | -140.24m | 763.12m | 138.00 | -- | 4.02 | -- | -- | -2.45 | -2.45 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -52.63 | -44.58 | -57.36 | -50.10 | -- | -- | -- | -881.92 | -- | -- | 0.00 | -- | -- | -- | -94.04 | -- | 49.73 | -- |
| Seres Therapeutics Inc | 7.13m | -250.16m | 767.81m | 431.00 | -- | 70.72 | -- | 107.72 | -2.36 | -2.36 | 0.066 | 0.0861 | 0.0203 | -- | -- | 16,538.28 | -71.10 | -47.06 | -93.38 | -60.78 | -- | -- | -3,509.50 | -231.45 | -- | -83.22 | 0.8256 | -- | -95.08 | -25.99 | -281.46 | -- | 16.00 | -- |
| POINT Biopharma Global Inc | 0.00 | -79.17m | 769.09m | 72.00 | -- | 2.45 | -- | -- | -0.8713 | -0.8713 | 0.00 | 2.97 | 0.00 | -- | -- | 0.00 | -26.26 | -- | -27.39 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -243.25 | -- | -- | -- |
| Innoviva Inc | 331.34m | 213.92m | 771.87m | 101.00 | 4.85 | 1.36 | 3.30 | 2.33 | 2.33 | 2.33 | 3.48 | 8.31 | 0.3071 | -- | 3.79 | 3,280,584.00 | 20.41 | 37.02 | 23.11 | 40.25 | 36.00 | -- | 66.48 | 93.57 | 2.87 | 1.27 | 0.4885 | -- | -15.45 | 8.81 | -19.53 | 9.78 | -- | -- |
| Allogene Therapeutics Inc | 243.00k | -332.63m | 774.51m | 359.00 | -- | 1.16 | -- | 3,187.27 | -2.32 | -2.32 | 0.0017 | 4.61 | 0.0003 | -- | -- | 676.88 | -35.85 | -29.66 | -37.95 | -31.41 | -- | -- | -136,885.60 | -3,191.05 | -- | -- | 0.00 | -- | -99.37 | -- | -29.43 | -- | -- | -- |
| Kiniksa Pharmaceuticals Ltd | 220.18m | 183.36m | 789.61m | 220.00 | 4.38 | 1.99 | 4.25 | 3.59 | 2.59 | 2.59 | 3.15 | 5.68 | 0.6359 | 1.81 | 18.12 | 1,000,818.00 | 52.96 | -28.40 | 61.06 | -32.52 | 89.60 | -- | 83.28 | -155.01 | 4.71 | -- | 0.00 | -- | 471.24 | -- | 216.11 | -- | 8.76 | -- |
| Exscientia PLC (ADR) | 29.99m | -121.81m | 797.13m | 287.00 | -- | 1.28 | -- | 26.58 | -1.00 | -1.00 | 0.2466 | 5.08 | 0.05 | 154.93 | 6.25 | 104,479.00 | -20.32 | -- | -23.43 | -- | -16.44 | -- | -406.22 | -- | 7.55 | -- | 0.013 | -- | 182.87 | -- | -120.94 | -- | -- | -- |
| Immunitybio Inc | 240.00k | -416.57m | 801.94m | 725.00 | -- | -- | -- | 3,341.41 | -1.04 | -1.04 | 0.0006 | -1.06 | 0.0006 | -- | 0.1489 | 331.03 | -100.41 | -94.40 | -- | -212.70 | -- | -- | -173,883.30 | -30,976.64 | -- | -5.48 | 2.97 | -- | -74.30 | 39.77 | -20.12 | -- | 23.34 | -- |
| ARS Pharmaceuticals Inc | 0.00 | -85.38m | 807.32m | 92.00 | -- | 1.14 | -- | -- | -2.43 | -2.43 | 0.00 | 7.44 | 0.00 | -- | -- | 0.00 | -27.38 | -- | -28.26 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -171.58 | -- | -- | -- |
Data as of Mar 22 2023. Currency figures normalised to POINT Biopharma Global Inc's reporting currency: US Dollar USD
39.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2022 | 9.18m | 8.69% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 4.89m | 4.63% |
| PFM Health Sciences LPas of 31 Dec 2022 | 4.63m | 4.39% |
| SSgA Funds Management, Inc.as of 31 Dec 2022 | 4.29m | 4.06% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 4.19m | 3.96% |
| Citadel Advisors LLCas of 31 Dec 2022 | 3.25m | 3.07% |
| Point72 Asset Management LPas of 31 Dec 2022 | 3.20m | 3.03% |
| Suvretta Capital Management LLCas of 31 Dec 2022 | 2.63m | 2.49% |
| Great Point Partners LLCas of 31 Dec 2022 | 2.54m | 2.41% |
| Avidity Partners Management LPas of 31 Dec 2022 | 2.43m | 2.30% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
